Simplified Cardiology Cases Management Handbook

Initial Assessment and Risk Stratification

Every cardiology patient requires immediate hemodynamic assessment and risk classification to guide management intensity and urgency. 1

Clinical Criteria for High-Risk Presentation

Cardiogenic shock indicators: SBP <90 mm Hg for 30 minutes, lactate >2 mmol/L, or need for vasopressors/inotropes to maintain blood pressure 1
Hemodynamic instability: Cardiac index <1.8 L/min/m² without support, cardiac power output <0.6W, or pulmonary artery pulsatility index <1.0 1
Acute coronary syndrome signs: New ST-segment changes ≥0.05 mV, elevated troponin >2x upper limit normal, or ongoing chest pain with ischemic ECG changes 2

Immediate Triage Decisions

Direct to cardiac catheterization lab: Patients with ST-elevation MI, cardiogenic shock with cardiac power output <0.6W, or refractory ischemia despite medical therapy 1, 2
Admit to cardiac intensive care unit: Any patient meeting cardiogenic shock criteria, hemodynamic instability, or high-risk features requiring invasive monitoring 1
Standard telemetry admission: Stable angina, controlled heart failure, or low-risk acute coronary syndrome without high-risk features 2

Acute Coronary Syndrome Management

Patients with suspected ACS require immediate ECG within 10 minutes, dual antiplatelet therapy, and risk-based invasive strategy selection. 2, 3

Immediate Interventions (First 24 Hours)

Antiplatelet therapy: Aspirin 162-325 mg loading dose plus clopidogrel 300-600 mg loading dose (avoid in planned urgent CABG within 5 days) 2, 4
Anticoagulation: Unfractionated heparin or low-molecular-weight heparin initiated immediately 2
Anti-ischemic therapy: Sublingual nitroglycerin 0.4 mg every 5 minutes x3 for ongoing chest pain, then IV nitroglycerin if pain persists (avoid if SBP <90 mm Hg or RV infarction) 2
Beta-blockers: Oral metoprolol or carvedilol within 24 hours UNLESS signs of heart failure, low-output state, or cardiogenic shock risk factors present 2

Invasive Strategy Timing

Emergent (<2 hours): STEMI with symptom onset <12 hours, cardiogenic shock, or electrical/hemodynamic instability 1, 3
Urgent (2-24 hours): NSTEMI with refractory ischemia, hemodynamic instability, or high-risk features (elevated troponin, dynamic ST changes, GRACE score >140) 2
Early invasive (24-72 hours): NSTEMI with intermediate risk features, diabetes, renal insufficiency, or reduced ejection fraction <40% 2

Post-PCI Management

Continue dual antiplatelet therapy: Aspirin 81 mg daily indefinitely plus clopidogrel 75 mg daily for minimum 12 months 4
Statin therapy: High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) initiated before discharge 2
ACE inhibitor/ARB: Start within 24 hours if LVEF ≤40%, heart failure signs, anterior MI, or diabetes (hold if SBP <100 mm Hg) 2
Cardiac rehabilitation referral: Mandatory Class I recommendation for all post-PCI patients to improve outcomes and reduce mortality 5

Cardiogenic Shock Protocol

Cardiogenic shock requires immediate invasive hemodynamic monitoring with pulmonary artery catheter to phenotype shock and guide mechanical circulatory support decisions. 1

Hemodynamic Phenotyping

LV-dominant shock: Cardiac power output <0.6W, pulmonary artery pulsatility index >1.0, right atrial pressure <15 mm Hg, PCWP >15 mm Hg 1
RV-dominant shock: Cardiac power output <0.6W, pulmonary artery pulsatility index <1.0, right atrial pressure >15 mm Hg, PCWP <15 mm Hg 1
Biventricular shock: Cardiac power output <0.6W, pulmonary artery pulsatility index >1.0, right atrial pressure >15 mm Hg, PCWP >15 mm Hg 1

Pharmacologic Management by Phenotype

LV-dominant with high afterload: Nitroprusside, milrinone, or dobutamine to reduce afterload and improve cardiac output 1
RV-dominant shock: Inhaled pulmonary vasodilators (nitric oxide or epoprostenol), minimize positive pressure ventilation, correct acidosis and hypoxemia 1
Refractory shock: Consider mechanical circulatory support if cardiac power output remains <0.6W despite optimal medical therapy 1

Mechanical Circulatory Support Indications

Percutaneous ventricular assist device: LV-dominant shock with cardiac index <2.2 L/min/m², lactate elevation, contraindications to other MCS 1
Venoarterial ECMO: Biventricular failure, RV-dominant shock with severe pulmonary hypertension, or risk of pulmonary hemorrhage with forced perfusion 1
Absolute contraindications: Anoxic brain injury, irreversible end-organ failure, prohibitive vascular access, or DNR status 1

Target Outcomes for MCS

30-day mortality: <1% 1
Complete heart block requiring pacemaker: <5-10% depending on device 1
Symptomatic improvement: >90% achieving ≥1 NYHA class improvement 1

Heart Failure Management

Heart failure patients require guideline-directed medical therapy optimization before discharge and enrollment in multidisciplinary disease management programs. 6, 7

Guideline-Directed Medical Therapy (HFrEF)

Quadruple therapy foundation: ACE inhibitor/ARB/ARNI + beta-blocker + mineralocorticoid receptor antagonist + SGLT2 inhibitor initiated before hospital discharge 7
Beta-blocker selection: Carvedilol, metoprolol succinate, or bisoprolol titrated to target doses (avoid in decompensated state) 2
Diuretic management: Loop diuretics for volume overload, titrate to euvolemia, monitor electrolytes and renal function 2

Multidisciplinary Care Team Structure

Core team members: Cardiologist, heart failure nurse, pharmacist, dietician, social worker, and palliative care specialist 6
Nurse-led case management: Medication reconciliation, symptom monitoring, weight tracking, and patient education on daily basis 6, 8
Pharmacist role: Medication optimization, drug interaction monitoring, and adherence counseling 6

Monitoring and Follow-Up

Post-discharge contact: Telephone follow-up within 3 days, clinic visit within 7-14 days 6
Self-monitoring education: Daily weights (report gain >2-3 lbs in 24 hours or >5 lbs in week), symptom diary, blood pressure tracking 6
Readmission prevention: Case management reduces cardiovascular events by 5 per 1000 individuals per year (NNT=200 to prevent 1 event annually) 8

Hypertrophic Cardiomyopathy

HCM patients require comprehensive 3-generation family history, genetic counseling, and referral to specialized HCM centers for invasive septal reduction therapy decisions. 9

Initial Diagnostic Evaluation

Physical examination maneuvers: Valsalva, squat-to-stand, passive leg raising to assess dynamic LVOT obstruction 9
Comprehensive family history: Document 3 generations for HCM diagnosis, unexplained sudden death, or cardiac events in relatives 9
Baseline testing: ECG, transthoracic echocardiography with provocation maneuvers, and cardiac MRI for tissue characterization 9

Septal Reduction Therapy Criteria

Indications: LVOT gradient ≥50 mm Hg at rest or with provocation, NYHA class III-IV symptoms despite maximal medical therapy 9
Center requirements: Procedures performed only at comprehensive or primary HCM centers meeting outcome benchmarks 9
Target outcomes: 30-day mortality <1%, symptomatic improvement >90%, residual LVOT gradient <50 mm Hg in >90% 9

Referral Indications to HCM Center

Complex management decisions: Genetic counseling, primary prevention ICD decision-making, sports participation counseling 9
Advanced procedures: Septal reduction therapy, catheter ablation for ventricular tachycardia, heart transplant evaluation 9
Shared decision-making: Full disclosure of risks/benefits for all treatment options including both surgical myectomy and alcohol septal ablation 9

Chronic Coronary Disease

Patients with stable coronary disease require comprehensive risk factor modification, optimal medical therapy, and functional testing to guide revascularization decisions. 10, 11

Medical Therapy Optimization

Antiplatelet therapy: Aspirin 81 mg daily (clopidogrel 75 mg if aspirin intolerant) 11
Statin therapy: High-intensity statin targeting LDL <70 mg/dL (consider <55 mg/dL in very high-risk patients) 10
Blood pressure control: Target <130/80 mm Hg using ACE inhibitor or ARB as first-line agent 10
Diabetes management: Metformin first-line, add SGLT2 inhibitor or GLP-1 receptor agonist if additional ASCVD risk factors present 10

Functional Testing Strategy

Exercise stress testing: First-line for patients with normal baseline ECG, not on digoxin, able to exercise 12
Stress imaging: Myocardial perfusion imaging or stress echocardiography if baseline ECG abnormalities, unable to exercise, or need to localize ischemia 12
Coronary CT angiography: Viable noninvasive option for initial evaluation of stable symptomatic coronary disease 7

Revascularization Decision-Making

Invasive strategy: Refractory angina despite optimal medical therapy, high-risk stress test features, or LVEF <40% with viable myocardium 11
Conservative strategy: Stable symptoms controlled on medical therapy, low-risk stress test, or patient preference after shared decision-making 11

Cardiac Amyloidosis

Cardiac amyloidosis requires multidisciplinary team approach with early diagnosis, accurate phenotyping (AL vs ATTR), and disease-specific therapy to improve survival and quality of life. 13

Diagnostic Algorithm

Clinical suspicion triggers: Heart failure with preserved ejection fraction, increased wall thickness on echo, low-voltage ECG despite thick walls, neuropathy 13
Serum free light chain testing: Essential first step to exclude AL amyloidosis before proceeding with nuclear imaging 13
Pyrophosphate (PYP) scan: Grade 2-3 cardiac uptake confirms ATTR-CM if serum free light chains negative 13
Endomyocardial biopsy: Reserved for equivocal cases or when AL amyloidosis suspected despite negative screening 13

Multidisciplinary Team Composition

Core specialists: Cardiology, hematology, neurology, nephrology, gastroenterology, genetics, palliative care 13
Support staff: Heart failure nurses, pharmacists, dieticians for comprehensive symptom management 13

Treatment Goals

Primary objectives: Improved survival and maximized quality of life through individualized disease journey 13
Disease-specific therapy: AL amyloidosis requires hematology-directed chemotherapy; ATTR-CM requires TTR stabilizers or silencers 13

Systems of Care and Quality Metrics

Regionalized cardiac care networks with dedicated shock teams and standardized protocols improve outcomes through early diagnosis, multidisciplinary care, and selective mechanical support use. 1, 14

Shock Team Structure

Activation criteria: Any patient meeting cardiogenic shock hemodynamic criteria or high-risk ACS features 1
Team composition: Interventional cardiologist, cardiac intensivist, cardiac surgeon, perfusionist, heart failure specialist 1
Response time: Team mobilization within 30 minutes of activation for optimal outcomes 1

STEMI Systems of Care

Prehospital 12-lead ECG: Transmission to receiving facility reduces door-to-balloon time and improves outcomes 14
Direct transfer protocols: Bypass non-PCI capable facilities for STEMI patients when transfer time <120 minutes 14
Post-cardiac arrest care: Comprehensive structured approach including targeted temperature management, coronary angiography, and multiorgan support 14

Quality Improvement Targets

Door-to-balloon time: <90 minutes for STEMI patients presenting to PCI-capable facility 14
Cardiac rehabilitation enrollment: >70% of eligible post-MI and post-PCI patients referred before discharge 5
Guideline-directed medical therapy: >90% of HFrEF patients discharged on quadruple therapy or documented contraindications 7

What is a comprehensive approach to cardiology cases management?

Have a follow-up question?